Search Results
Your search for all items matches 36858 pages
Showing 1 - 50cfDNA Fragmentomics Plus Methylation Analysis May Improve Detection of Precancerous Colorectal Lesions
A blood-based assay combining cell-free DNA (cfDNA) fragmentomics with droplet digital PCR–based methylation analysis improved detection of early-stage colorectal cancer (CRC) and precancerous lesions, according to findings presented at the 2026 ASCO Breakthrough meeting in Singapore. In this...
In Cancer Trials, Federal and Industry Sponsors Play Complementary Roles
A comparative study of the cancer clinical trial portfolios supported by federal funding vs industry funding reveals they have distinct, interdependent roles in cancer research. The findings were published by Unger et al in JAMA Oncology. The analysis found that, whereas industry trials were more...
Study Evaluates Chemotherapy-Free Quadruplet in HR-Positive, HER2-Positive Metastatic Breast Cancer
Researchers have reported that a chemotherapy-free combination of four targeted therapies showed encouraging results in patients with hormone receptor (HR)-positive, HER2-positive metastatic breast cancer, offering a potential first-line treatment option that may be more convenient for some...
ASCO Remembers Dr. Harold P. Freeman, Preeminent Health Equity Expert and Pioneer of Patient Navigation
ASCO joins the oncology community in mourning the death of Harold P. Freeman, MD, a world-renowned expert on and advocate for health equity and the pioneer of patient navigation services in oncology. Dr. Freeman passed away on August 11, 2026; he was 93. After completing medical training at Howard ...
Prostate Cancer: NRG-GU005 Defines Trade-Offs Between SBRT and Moderately Hypofractionated IMRT
In the international phase III NRG-GU005 trial, stereotactic body radiotherapy (SBRT) improved bowel-related quality of life vs moderately hypofractionated intensity-modulated radiotherapy (IMRT) in patients with favorable intermediate-risk prostate cancer. However, Ellis et al reported in JAMA...
WashU Medicine Appoints New Chief of Head and Neck Surgery
Andrés M. Bur, MD, FACS, has been named Chief of the Division of Head and Neck Surgery in the Department of Otolaryngology–Head & Neck Surgery at WashU Medicine and Co-Director of the Robert Ebert and Greg Stubblefield Head and Neck Tumor Center at Siteman Cancer Center, based at Barnes-Jewish...
Expanded EHR Data May Improve Prediction of Early Adverse Events After AML Induction Chemotherapy
Patients with acute myeloid leukemia (AML) frequently experienced unplanned hospital readmission or death within 30 days after discharge following induction chemotherapy, according to findings reported by Chae et al in JCO Clinical Cancer Informatics. The investigators found that incorporating...
Cleveland Clinic President Discusses Friday’s AI Summit for Health-Care Professionals
Artificial intelligence (AI) is one of the most transformative technological advancements of our time, poised to revolutionize every aspect of our lives, including health care. On August 28, Cleveland Clinic, in collaboration with the College of Healthcare Information Management Executives (CHIME), ...
FDA Approves Daraxonrasib for Metastatic Pancreatic Adenocarcinoma
On August 26, the U.S. Food and Drug Administration (FDA) approved daraxonrasib (Rasonque), an inhibitor of the RAS GTPase family, for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy....
Colorectal Cancer May Cause Peripheral Neuropathy Before Treatment, Preclinical Study Finds
Colorectal cancer may result in tumor-related inflammation that damages peripheral nerves before even starting cancer treatment, according to preclinical findings published in Nature Communications. This damage may be the reason why colorectal cancer survivors are more likely to develop peripheral...
Dr. Gary R. Morrow, a Pioneer in Cancer Research, Dies at 82
Gary R. Morrow, PhD, MS, died on July 7, 2026, at age 82, from complications due to pneumonia and a 16-year history of prostate cancer, according to an obituary shared by his family. Over nearly 5 decades at the University of Rochester Wilmot Cancer Institute, Dr. Morrow brought in $100 million in ...
Research Finds Supercentenarians Have an Abundance of Cancer-Killing Immune Cells
The human immune system has specialized cells called CD4 cytotoxic T lymphocytes (CD4 CTLs), which have been shown to kill tumor cells in some cancers. These cells multiply in a process called clonal expansion to help fight infection. In a study published by Hashimoto in Cell Reports, researchers...
ASCO Remembers Supportive Care and Symptom Management Pioneer Gary R. Morrow, PhD, MS
ASCO joins the oncology community in mourning the death of Gary R. Morrow, PhD, MS, who passed away on July 7, 2026; Dr. Morrow was 82. Dr. Morrow was a pioneer in the field of supportive care, and his research on the potentially debilitating side effects of cancer treatment, including nausea,...
FDA Approves Zanidatamab Combination Regimens for HER2-Positive Gastric, GEJ, or Esophageal Cancer
On August 25, 2026, the U.S. Food and Drug Administration (FDA) approved zanidatamab-hrii (Ziihera) for two indications, including: in combination with fluoropyrimidine- and platinum-containing chemotherapy and tislelizumab-jsgr (Tevimbra), as first-line treatment for adults with HER2-positive...
The Mid-Career Oncologist in LMIC Regions: Navigating Disparities, Avoiding Burnout, and Delivering Optimal Care
To be a mid-career oncologist is to occupy an emotionally and physically taxing space within a trying clinical environment. We may be 10 years and beyond our post-training. We are no longer trainees who may be protected by institutional shields, nor are we established senior department heads with...
Long-Term Survivors of Hodgkin Lymphoma May Face Elevated Health Risks, Study Finds
Adults who have survived Hodgkin lymphoma for at least 5 years may face significantly elevated long-term health risks and cancer and noncancer mortality, according to a new study led by researchers at The University of Texas MD Anderson Cancer Center. The retrospective population-based study,...
Preoperative Weight-Loss Program Shows Feasibility Before Endometrial Cancer Surgery
A short-term, intensive weight-loss program before surgery was feasible and produced meaningful weight loss in women with endometrial cancer and excess weight in the randomized ENDO-CARE trial. The intervention was also associated with fewer postoperative complications, although the study was not...
Metabolic Syndrome Frequently Documented During First Year of ADT-ARPI Therapy in Prostate Cancer
Metabolic abnormalities were frequently documented during the first year after men with prostate cancer began concurrent androgen-deprivation therapy (ADT) and an androgen receptor pathway inhibitor (ARPI), according to a large retrospective cohort study led by Amy L. Shaver, PhD, PharmD, MPH, and...
Phase III OPTIMA Trial: Many Patients With ER-Positive, HER2-Negative Breast Cancer May Be Able to Avoid Chemotherapy
New results from the international, randomized, phase III OPTIMA trial indicate that select patients with clinically high-risk, estrogen receptor–positive, HER2-negative early breast cancer who have a low risk of recurrence based on tumor gene expression testing may be able to safely avoid...
Cancer Epidemiologist Joseph F. Fraumeni, Jr, MD, Dies at 93
The oncology community is mourning the loss of renowned physician-scientist and cancer epidemiologist Joseph F. Fraumeni, Jr, MD, who died on June 22, 2026, at the age of 93. During a career spanning more than 5 decades at the National Cancer Institute (NCI), Dr. Fraumeni fundamentally changed the...
Living Guideline Adds Repotrectinib and Zongertinib as Treatment Options for Advanced NSCLC With Driver Alterations
ASCO has issued a new update to its Living Guideline on therapy for stage IV non–small cell lung cancer (NSCLC) with driver alterations, including new recommendations for two therapies: repotrectinib, a ROS1 tyrosine kinase inhibitor (TKI), and zongertinib, a HER2-selective, EGFR-sparing TKI.1 The...
Lori J. Pierce, MD, FASCO, Named Distinguished University Professor, University of Michigan
University of Michigan (U-M) Professor Lori J. Pierce, MD, is one of six U-M faculty members recognized for their outstanding teaching and service with one of the university’s prestigious honors, the Distinguished University Professorship. The U-M Board of Regents recently approved the...
FDA Seeks Public Input Relating to Regulatory Considerations for Generative AI–Enabled Medical Devices
The U.S. Food and Drug Administration (FDA) has released a discussion paper regarding factors that go into the regulation of generative artificial intelligence (AI)–enabled medical devices and is asking for public feedback, focusing on areas such as risk assessment, premarket evaluation, and...
Early Histotripsy Use for Liver Tumors Raises Questions About Patient Selection
Histotripsy was cleared by the U.S. Food and Drug Administration in 2023 for the treatment of primary and metastatic liver tumors. In a research letter published in JAMA Network Open, Sears et al reported findings from a retrospective cohort study evaluating national practice patterns and...
INTerpath-001 Trial of mRNA-Based Individualized Neoantigen Therapy Meets Primary and Key Secondary Endpoints in Patients With High-Risk Resected Melanoma
Merck and Moderna, Inc. have announced positive topline results from the phase III INTerpath-001 trial (ClinicalTrials.gov identifier NCT05933577) evaluating adjuvant treatment with intismeran autogene (intismeran; V940 or mRNA-4157), a novel investigational mRNA-based individualized neoantigen...
Pilots and Flight Attendants Show Elevated Radiation-Related Cancer Mortality
Flight attendants and pilots had the highest and second-highest risk-adjusted percentages of deaths from radiation-related cancers, respectively, among more than 500 occupations in the United States, according to the results of a population-based analysis reported by Patel et al in a research...
Chemotherapy, Immunotherapy, and Targeted Therapy in Advanced, Refractory Malignancies
Our data on a triplet combination of chemotherapy, immune checkpoint inhibitors, and targeted therapy (ICTriplex) in advanced and refractory malignancies were presented in June at the 2026 ASCO Breakthrough Conference in Singapore. ICTriplex is a therapeutic strategy; it is not a single specific...
Study Supports Personalized Weight-Loss Intervention for Breast Cancer Survivors
A personalized approach to obesity treatment may help breast cancer survivors improve their long-term health by identifying early which patients need more than behavioral lifestyle intervention alone. The phase II Adaptive Nutrition and Exercise Weight Loss (A-NEW) trial found that breast cancer...
County-Level Medical Debt Linked to Advanced-Stage Cancers, Worse Survival Among Newly Diagnosed U.S. Adults
Individuals diagnosed with cancer in the United States often bear significant health-care costs and productivity losses, with over half incurring cancer-related medical debt. In response, cancer patients and survivors often delay or forgo necessary care; cut back on food, clothing, and basic...
Mosunetuzumab With Response-Adapted Therapy in Previously Untreated NHL
According to the results of a phase II study reported by Lynch et al in the Journal of Clinical Oncology, a chemotherapy-free approach using subcutaneous single-agent mosunetuzumab, or, for patients without an initial complete response, mosunetuzumab followed by polatuzumab vedotin plus...
Cleveland Clinic to Host Second Annual AI Summit for Health-Care Professionals
AI is one of the most transformative technological advancements of our time, poised to revolutionize every aspect of our lives, including health care. On August 28, 2026, Cleveland Clinic in collaboration with the College of Healthcare Information Management Executives (CHIME), will host the Second ...
Digital Integrative Medicine Program Improves Overall Survival in Patients Undergoing Systemic Cancer Treatment
Guest Editor’s Note: Cancer and its treatments often contribute to troubling symptoms, including fatigue, which has been correlated with poor treatment-related outcomes, including overall survival, in patients with cancer. Growing evidence indicates that mind-body therapies such as meditation,...
Adding a Radiopharmaceutical to Standard Therapy in mRCC Does Not Improve Skeletal Events
The addition of radium-223, an alpha-emitting bone-seeking radioisotope, to cabozantinib, a tyrosine kinase inhibitor, did not improve skeletal-related outcomes in patients with metastatic renal cell carcinoma and bone metastases, according to findings from the randomized phase II RADICAL trial...
Charles W.M. Roberts, MD, PhD, Named President and Chief Executive Officer of St. Jude Children’s Research Hospital
The Board of Governors of St. Jude Children’s Research Hospital have announced Charles W.M. Roberts, MD, PhD, Executive Vice President and current Director of the St. Jude Comprehensive Cancer Center, as its next President and Chief Executive Officer. The announcement follows an extensive...
Is Excess Adiposity Linked to Vertebral Fracture Progression in Aromatase Inhibitor–Treated Early Breast Cancer?
Among patients with early breast cancer receiving aromatase inhibitors, excess adiposity emerged as a novel risk factor for vertebral fracture progression, whereas higher muscle mass was protective, according to a retrospective cohort study by Schivardi et al published in JAMA Network Open. “These...
Genomic Profiles and Adjuvant Chemotherapy Outcomes in Resected Pancreatic Cancer
Tumor genomic alterations and transcriptomic subtypes may provide prognostic information in patients with resected pancreatic ductal adenocarcinoma (PDAC), but most did not predict differential benefit from adjuvant modified FOLFIRINOX (mFOLFIRINOX) vs gemcitabine, according to an analysis of the...
Navigating Early Relapse in Multiple Myeloma: New Evidence from the 2026 ASCO and EHA Congresses
“The future of cancer therapy lies in rational combinations that harness the immune system while preserving patient quality of life.” —Vincent T. DeVita, MD The treatment landscape for relapsed/refractory (R/R) multiple myeloma continues to evolve rapidly as T-cell–redirecting bispecific...
Rezatapopt Shows Activity in TP53 Y220C–Mutated Advanced Ovarian Cancer
Single-agent rezatapopt produced “very deep and durable responses” in heavily pretreated patients with TP53 Y220C–mutated advanced ovarian cancer, according to updated results from the pivotal phase II PYNNACLE trial presented at the 2026 ASCO Breakthrough meeting in Singapore. The analysis was...
Consumption of Sugar-Sweetened Beverages May Raise Gastric Cancer Risk
Approximately 65% of U.S. adults report consuming one or more sugar-sweetened beverages every day. Researchers found that consuming these drinks daily was associated with an increased risk of developing gastric cancer, whereas consumption of artificially sweetened beverages was not associated with...
High-Risk ERBB2-Negative Breast Cancer: Adding Dual Checkpoint Blockade to Neoadjuvant Chemotherapy
The addition of dual PD-1 and LAG-3 inhibition with cemiplimab-rwlc and fianlimab to standard paclitaxel-based neoadjuvant chemotherapy resulted in improved pathologic complete response rates in patients with early-stage, high-risk ERBB2 (formerly HER2 or HER2/neu)-negative breast cancer, according ...
TACE Plus Thermal Ablation Improves Survival in Unresectable HCC
Transarterial chemoembolization (TACE) followed by thermal ablation was associated with improved survival outcomes compared with TACE alone in patients with liver-confined, unresectable hepatocellular carcinoma, according to findings from the phase III TORCH trial published by Lyu et al in JAMA...
AASLD Publishes Landmark North American Framework to Advance Treatment Decisions for HCC
The American Association for the Study of Liver Diseases (AASLD) recently announced the publication of BEACON-HCC, a landmark multidisciplinary consensus now available online in HEPATOLOGY. The consensus was developed by 20 North American experts representing hepatology, medical oncology, surgery,...
Adding Irinotecan to Preoperative Chemoradiotherapy Does Not Improve Outcomes in Locally Advanced Rectal Cancer
In the phase III ARISTOTLE trial, adding irinotecan to preoperative capecitabine-based chemoradiotherapy did not improve disease-free survival in patients with locally advanced rectal cancer, and was also associated with substantially more severe toxicity. The findings were reported by...
Early Intravesical Pirarubicin Improves Relapse-Free Survival in Upper Tract Urothelial Carcinoma
A single intravesical dose of the antracycline pirarubicin administered within 24 hours after radical nephroureterectomy significantly improved relapse-free survival in patients with upper tract urothelial carcinoma. The benefit was driven mainly by fewer new bladder tumors after surgery, while...
AI Model Predicts TP53 Status, Tumor Type, and Survival From Routine H&E Slides
Using an artificial intelligence (AI) model, researchers were able to simultaneously predict cancer subtype, TP53 mutation status, and survival outcomes across 32 solid tumors from routine hematoxylin and eosin (H&E)–stained whole-slide images, according to findings published in The American...
Darovasertib Plus Crizotinib May Set New First-Line Standard in HLA-A2–Negative Metastatic Uveal Melanoma
First-line treatment with darovasertib plus crizotinib significantly improved progression-free survival and response rates compared with investigator’s choice of treatment in patients with HLA-A2–negative metastatic uveal melanoma, according to primary results from the phase IIb portion of the...
Can Newborn Genetic Testing Identify Cancer Predisposition Genes?
Expanding routine newborn screening to include genetic testing could identify genes associated with cancer risk and flag babies who may be at risk of later developing pediatric cancers, according to findings published in Nature Communications. Newborns in the United States routinely undergo...
Cretostimogene Grenadenorepvec in BCG-Unresponsive Non–Muscle-Invasive Bladder Cancer
In the phase III BOND-003 Cohort C trial, intravesical cretostimogene grenadenorepvec, an oncolytic immunotherapy, produced complete responses in three-quarters of patients with high-risk, bacillus Calmette-Guérin (BCG)-unresponsive, non–muscle-invasive bladder cancer (NMIBC) with carcinoma in...
QOL Impact of Postmastectomy Chest Wall Radiotherapy: 5-Year Follow-up
In the 5-year quality-of-life (QOL) analysis of the phase III SUPREMO trial published in The Lancet Oncology, Velikova et al found that women with intermediate-risk breast cancer who received postmastectomy chest wall radiotherapy experienced modestly worse local chest wall symptoms at 5 years, but ...
What Is the Optimal PSA to Determine Prostate Cancer Treatment Efficacy?
After treatment for metastatic prostate cancer, a decline in prostate-specific antigen (PSA) levels is an indicator that the treatment is effective. Findings from a recent real-world study published by Freedland et al in the journal Cancer indicate that reaching a PSA level below 0.2 ng/mL is an...
